Postmenopausal Osteoporosis - Pipeline Insight, 2025
Description
DelveInsight’s, “Postmenopausal Osteoporosis - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Postmenopausal Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Postmenopausal Osteoporosis: Overview
The World Health Organization (WHO) defines menopause as the complete cessation of menstruation in a woman for one year or more. Perimenopause is irregular menstruation before menopause. Its duration is variable. The average age of Indian women is 46.2 years at menopause. Postmenopausal osteoporosis (PMO) is defined as a generalized skeletal disorder in which because of decreased bone density or deteriorating bone quality there is increased risk of fracture. The bone turnover is increased in early peri menopausal period leading to a net bone loss. Postmenopausal osteoporosis is linked with the deficiency of estrogen that occurs with the cessation of the function of the ovaries as age progresses. The function of estrogen in the bone remodeling process is very well understood after years of research; estrogen plays a part in both the formation of bone as well as the prevention of the resorption of bone. A diagnosis can be made by dual-energy X-ray absorptiometry (DEXA). It is the gold standard and can spot low bone density at particular sites. The treatment options are selected according to the severity and rate of progression and factors pertaining to each patient.
At menopause the normal bone turnover cycle is impaired by estrogen deficiency. This may be due to the presence of estrogen receptors in osteoclast progenitor cells and multi-nucleated osteoclasts. The osteoclastic resorption activity increases while the osteoblastic activity decreases. As a result, the amount of bone resorbed exceeds the amount deposited, which leads to a net loss of bone. The increase of overall bone resorption is due to a weakened inhibition effect due to the reduction of available estrogen on both osteoclastogenesis and osteoclast activity. The enhanced expression of cytokines known to stimulate osteoclastogenesis, such as IL-1, IL-6, and TNF, or enhanced expression of M-CSF (macrophage colony-stimulating factor) and RANKL in osteoblasts/stromal cells may also play an important role. The stimulatory effect of estrogen on bone formation is less-well-understood, but may be mediated by estrogen-receptor-responsive elements on promoters for genes involved in bone matrix biosynthesis, including type I collagen, or cytokines believed to be important for coupling of bone resorption and bone formation. During the first phase of menopausal bone loss women are in marked negative calcium balance.
The symptoms of postmenopausal osteoporosis usually aren't obvious. Osteoporosis tends to develop slowly and silently, and many people don't realize they have the condition until a bone fractures, or breaks, suddenly. It is characterized by a decrease in bone density and quality, which can lead to an increased risk of fractures. The condition often develops without noticeable symptoms until a fracture occurs. Common symptoms and signs of postmenopausal osteoporosis may include Bone Fractures, Back Pain, Loss of Height, Stooped Posture, Decreased Grip Strength and Joint pain.
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. In postmenopausal women at high risk of fractures, initial treatment is recommend with bisphosphonates (alendronate, risedronate, zoledronic acid, and ibandronate) or denosumab as an alternative initial treatment, to reduce fracture risk. In postmenopausal women with osteoporosis at very high risk of fracture, such as those with severe or multiple vertebral fractures, Physicians recommend teriparatide treatment for up to 2 years for the reduction of vertebral and nonvertebral fractures. Preventive no pharmacological treatment includes adequate dietary intakes of key bone nutrients such as calcium, vitamin D and protein contribute to bone health and reduce thereby the risk of osteoporosis and of fracture later in life. Dietary sources of calcium are the preferred option and calcium supplementation should only be targeted to those who do not get sufficient calcium from their diet and who are at high risk for osteoporosis.
""Postmenopausal Osteoporosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal Osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Postmenopausal Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postmenopausal Osteoporosis Emerging Drugs
Further product details are provided in the report……..
Postmenopausal Osteoporosis: Therapeutic Assessment
This segment of the report provides insights about the different Postmenopausal Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:
Postmenopausal Osteoporosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Postmenopausal Osteoporosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postmenopausal Osteoporosis drugs.
Postmenopausal Osteoporosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Postmenopausal Osteoporosis: Overview
The World Health Organization (WHO) defines menopause as the complete cessation of menstruation in a woman for one year or more. Perimenopause is irregular menstruation before menopause. Its duration is variable. The average age of Indian women is 46.2 years at menopause. Postmenopausal osteoporosis (PMO) is defined as a generalized skeletal disorder in which because of decreased bone density or deteriorating bone quality there is increased risk of fracture. The bone turnover is increased in early peri menopausal period leading to a net bone loss. Postmenopausal osteoporosis is linked with the deficiency of estrogen that occurs with the cessation of the function of the ovaries as age progresses. The function of estrogen in the bone remodeling process is very well understood after years of research; estrogen plays a part in both the formation of bone as well as the prevention of the resorption of bone. A diagnosis can be made by dual-energy X-ray absorptiometry (DEXA). It is the gold standard and can spot low bone density at particular sites. The treatment options are selected according to the severity and rate of progression and factors pertaining to each patient.
At menopause the normal bone turnover cycle is impaired by estrogen deficiency. This may be due to the presence of estrogen receptors in osteoclast progenitor cells and multi-nucleated osteoclasts. The osteoclastic resorption activity increases while the osteoblastic activity decreases. As a result, the amount of bone resorbed exceeds the amount deposited, which leads to a net loss of bone. The increase of overall bone resorption is due to a weakened inhibition effect due to the reduction of available estrogen on both osteoclastogenesis and osteoclast activity. The enhanced expression of cytokines known to stimulate osteoclastogenesis, such as IL-1, IL-6, and TNF, or enhanced expression of M-CSF (macrophage colony-stimulating factor) and RANKL in osteoblasts/stromal cells may also play an important role. The stimulatory effect of estrogen on bone formation is less-well-understood, but may be mediated by estrogen-receptor-responsive elements on promoters for genes involved in bone matrix biosynthesis, including type I collagen, or cytokines believed to be important for coupling of bone resorption and bone formation. During the first phase of menopausal bone loss women are in marked negative calcium balance.
The symptoms of postmenopausal osteoporosis usually aren't obvious. Osteoporosis tends to develop slowly and silently, and many people don't realize they have the condition until a bone fractures, or breaks, suddenly. It is characterized by a decrease in bone density and quality, which can lead to an increased risk of fractures. The condition often develops without noticeable symptoms until a fracture occurs. Common symptoms and signs of postmenopausal osteoporosis may include Bone Fractures, Back Pain, Loss of Height, Stooped Posture, Decreased Grip Strength and Joint pain.
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. In postmenopausal women at high risk of fractures, initial treatment is recommend with bisphosphonates (alendronate, risedronate, zoledronic acid, and ibandronate) or denosumab as an alternative initial treatment, to reduce fracture risk. In postmenopausal women with osteoporosis at very high risk of fracture, such as those with severe or multiple vertebral fractures, Physicians recommend teriparatide treatment for up to 2 years for the reduction of vertebral and nonvertebral fractures. Preventive no pharmacological treatment includes adequate dietary intakes of key bone nutrients such as calcium, vitamin D and protein contribute to bone health and reduce thereby the risk of osteoporosis and of fracture later in life. Dietary sources of calcium are the preferred option and calcium supplementation should only be targeted to those who do not get sufficient calcium from their diet and who are at high risk for osteoporosis.
""Postmenopausal Osteoporosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal Osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal Osteoporosis.
This segment of the Postmenopausal Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postmenopausal Osteoporosis Emerging Drugs
- RGB-14-P: Gedeon Richter
- Bmab 1000: Biocon Biologics
- AGA2118: Angitia Biopharmaceuticals
Further product details are provided in the report……..
Postmenopausal Osteoporosis: Therapeutic Assessment
This segment of the report provides insights about the different Postmenopausal Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Postmenopausal Osteoporosis
- There are approx. 8+ key companies which are developing the therapies for Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. Registration include, Gedeon Richter.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Postmenopausal Osteoporosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Postmenopausal Osteoporosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postmenopausal Osteoporosis drugs.
Postmenopausal Osteoporosis Report Insights
- Postmenopausal Osteoporosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Postmenopausal Osteoporosis drugs?
- How many Postmenopausal Osteoporosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postmenopausal Osteoporosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal Osteoporosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Postmenopausal Osteoporosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Gedeon Richter
- Biocon Biologics
- Angitia Biopharmaceuticals
- HJB (Hangzhou) Co., Ltd.
- Celltrion
- Samsung Bioepis Co., Ltd.
- RGB-14-P
- Bmab 1000
- AGA2118
- TST002
- CT-P41
- SB16
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Postmenopausal Osteoporosis: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Postmenopausal Osteoporosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Registration)
- Comparative Analysis
- RGB-14-P: Gedeon Richter
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- AGA2118: Angitia Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Postmenopausal Osteoporosis Key Companies
- Postmenopausal Osteoporosis Key Products
- Postmenopausal Osteoporosis- Unmet Needs
- Postmenopausal Osteoporosis- Market Drivers and Barriers
- Postmenopausal Osteoporosis- Future Perspectives and Conclusion
- Postmenopausal Osteoporosis Analyst Views
- Postmenopausal Osteoporosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
